Indica Labs vs PathAI (2026)
If your failure mode is buying a workspace whose underlying AI you cannot govern, and scanner freedom matters most, start with Indica Labs. If the algorithms themselves are the thing you are buying, start with PathAI. The split is whether you are purchasing the workspace or the models inside it. Indica is a cleared platform that runs digital primary diagnosis with no AI required at all, and it holds the widest scanner and interoperability freedom in the category. PathAI grades A on AI centrality because the models are the company, and its AIM-MASH tool is the first pathology Drug Development Tool qualified by both the FDA and the EMA, a bar above clearance. The catch on PathAI is ownership: its pending move into Roche puts neutrality toward outside algorithms in question in a way Indica does not face.
- Widest scanner and interoperability freedom in the category: cleared across two scanner manufacturers (Hamamatsu K232833, Leica K252762), DICOM compatible, and able to host outside algorithms, which earns the only A on interoperability among these platforms.
- Broadest cleared scope: authorized for primary diagnosis of surgical pathology slides generally rather than one tumor type, spanning clinical, research, trials, and companion diagnostic work.
- Disciplined regulatory disclosure: states plainly that HALO AP Dx is the cleared product, that HALO AP is research use only, and that clearance is tied to named scanners.
- The AI is the substance, not a feature layered onto a platform: more than 20 validated algorithms and an A on AI centrality, so if model quality is what you are paying for, this is the platform built on it.
- The deepest regulatory pedigree for the algorithms: AIM-MASH is the first pathology Drug Development Tool qualified by both the FDA and the EMA, and the 2025 platform clearance carries a Predetermined Change Control Plan, so model updates follow a path agreed in advance rather than arriving silently.
- Commercial and evidence validation Indica cannot match: a national reference laboratory licensed the platform for its own operations, and Roche agreed to acquire the company for up to roughly 1.05 billion dollars.
This comparison is published by AI Health Index, an independent research platform that compares healthcare AI vendors objectively. Indica Labs and PathAI are each graded against the same capability taxonomy, from each vendor's own public materials and the regulatory record, under the AI Health Index verification standard. No vendor pays for placement, and no vendor has reviewed this page. How this evidence is graded
Plain facts
| Fact | Indica Labs | PathAI |
|---|---|---|
| Primary category | Digital Pathology AI | Digital Pathology AI |
| Founded | 2007 | 2016 |
| Headquarters | Albuquerque, New Mexico, United States | Boston, Massachusetts, United States |
| Website | indicalab.com | pathai.com |
Side by Side
Each record in one paragraph
Written to be quoted whole. Each paragraph states what the AI Health Index verified about the vendor, with the caveats attached. Generated from this pair’s live capability grades, so it moves when a grade moves.
The AI Health Index awards Indica Labs its top capability grade on several axes, including FDA and Regulatory Status, EHR and Interoperability Depth and Deployment Model and Data Residency. Set against PathAI, Indica Labs grades higher on EHR and Interoperability Depth, Deployment Model and Data Residency and Setting and Specialty Coverage. Grades reflect evidence the AI Health Index could verify at the last review, so a low grade records disclosure the vendor has not published rather than a capability it has been shown to lack.
Source: AI Health Index, July 2026
The AI Health Index awards PathAI its top capability grade on several axes, including AI Centrality, Model and Technology Transparency and Clinical and Operational Evidence. Set against Indica Labs, PathAI grades higher on several axes, including AI Centrality, Model and Technology Transparency and Clinical and Operational Evidence. Grades reflect evidence the AI Health Index could verify at the last review, so a low grade records disclosure the vendor has not published rather than a capability it has been shown to lack.
Source: AI Health Index, July 2026
Questions buyers ask
Should we choose Indica Labs or PathAI?
On the axes where the AI Health Index separates them, Indica Labs grades higher on EHR and Interoperability Depth, Deployment Model and Data Residency and Setting and Specialty Coverage, and PathAI grades higher on several axes, including AI Centrality, Model and Technology Transparency and Clinical and Operational Evidence. PathAI leads on the greater share of scored axes, but the split means the decision turns on which constraint is binding rather than on an overall winner.
Where do Indica Labs and PathAI differ most?
The widest separation the AI Health Index records between Indica Labs and PathAI is on AI Centrality, where Indica Labs grades C and PathAI grades A. That axis sits in the AI Capability group, so it should carry the most weight for a buyer whose binding constraint is how much of the work the model itself is trusted to do.
Where do Indica Labs and PathAI grade the same?
The AI Health Index grades Indica Labs and PathAI the same on several axes, including Autonomy and Oversight Model, Model Supply Chain Disclosure and AI Safety and PHI Stewardship. Neither holds an advantage the index can evidence on those axes, so they should not carry weight in a selection between these two.
Related comparisons
Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the Digital Pathology AI page.
Neither vendor publishes pricing. PathAI's ownership is in transition through a Roche merger expected to close in the second half of 2026, moving it into Roche's Diagnostics division; external analysts have flagged whether an open algorithm host stays neutral under a diagnostics owner with its own assay pipeline, and buyers should confirm how existing licensing survives the deal.
PathAI also publishes no SOC 2, HITRUST, or ISO 27001 attestation, notable because its direct competitor Ibex publishes the full set. Indica couples clearance to specific scanners, so hardware choice and software cost are one decision rather than two, and it documents its own AI models thinly; it states HIPAA compliance but publishes no BAA or security attestation beyond ISO 13485 and 21 CFR Part 11.